About CardioAbstracts
HFSA’s CardioAbstracts program delivers expert-led discussions on recently presented clinical trial data in a convenient, interactive format. This 45-minute live seminar features Q&A with leading clinicians, recordings, and downloadable resources available for on-demand learning. This program is designed to support diverse learning styles and provide practical insights for clinicians specializing in heart failure care.
People living with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) experience high rates of mortality and morbidity. Findings from the HELIOS-B trial showed that treatment with vutrisiran reliably reduced the risk of all-cause mortality (ACM) and cardiovascular (CV) mortality, CV hospitalizations, heart failure (HF) hospitalizations, and urgent HF visits compared to placebo. In this session, HFSA's faculty will discuss newly presented results from the open-label extension study and a post hoc analysis of the HELIOS-B trial.
HELIOS-B: 12-Month Results from the Open-Label Extension Period of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Evidence of Fewer Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Compared with Placebo: Analysis from HELIOS-B
Effects of Vutrisiran on Measures of Cardiac Structure, Function and Amyloid Burden by Cardiovascular Magnetic Resonance from the HELIOS-B Trial
Vutrisiran Improved Outcomes Versus Placebo in Patients with Transthyretin Amyloidosis with Cardiomyopathy and Severe Chronic Kidney Disease: Post Hoc Analysis of HELIOS-B
Speaker: Farooq Sheikh, MD
Georgetown University School of Medicine
Speaker: Marianna Fontana, MD, PhD
Department of Cardiac MRI, Royal Free London NHS Foundation Trust, London, UK; Division of Medicine, University College London, London, UK.
Speaker: Pablo Garcia-Pavia, MD, PhD
Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, CIBERCV, and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
The supporter for this program is Alnylam Pharmaceuticals.
Cardiologists, interventional cardiologists, primary care physicians, cardiac surgeons, internists, nurse practitioners, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers who care for patients with heart failure.
CardioAbstracts is a non-accredited educational program that utilizes an online format to provide timely information and the opportunity to interact with faculty and ask questions to find more information about recently presented results from the open-label extension study and a post hoc analysis of the HELIOS-B trial.